PuSH - Publication Server of Helmholtz Zentrum München: Trans-right ventricle and transpulmonary metabolite gradients in human pulmonary arterial hypertension.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Chouvarine, P.* ; Giera, M.* ; Kastenmüller, G. ; Artati, A. ; Adamski, J. ; Bertram, H.* ; Hansmann, G.*

Trans-right ventricle and transpulmonary metabolite gradients in human pulmonary arterial hypertension.

Heart 106, 1332-1341 (2020)

Publ. Version/Full Text

Research data

DOI

PMC

	Open Access Gold (Paid Option)

Abstract
Metrics
Extra information

Objective While metabolic dysfunction occurs in several pulmonary arterial hypertension (PAH) animal models, its role in the human hypertensive right ventricle (RV) and lung is not well characterised. We investigated whether circulating metabolite concentrations differ across the hypertensive RV and/or the pulmonary circulation, and correlate with invasive haemodynamic/echocardiographic variables in patients with PAH.Methods Prospective EDTA blood collection during cardiac catheterisation from the superior vena cava (SVC), pulmonary artery (PA) and ascending aorta (AAO) in children with PAH (no shunt) and non-PAH controls (Con), followed by unbiased screens of 427 metabolites and 836 lipid species and fatty acids (FAs) in blood plasma (Metabolon and Lipidyzer platforms). Metabolite concentrations were correlated with echocardiographic and invasive haemodynamic variables.Results Metabolomics/lipidomics analysis of differential concentrations (false discovery rate<0.15) revealed several metabolite gradients in the trans-RV (PA vs SVC) setting. Notably, dicarboxylic acids (eg, octadecanedioate: fold change (FC)_Control=0.77, FC_PAH=1.09, p value=0.044) and acylcarnitines (eg, stearoylcarnitine: FC_Control=0.74, FC_PAH=1.21, p value=0.058). Differentially regulated metabolites were also found in the transpulmonary (AAO vs PA) setting and between-group comparisons, that is, in the SVC (PAH-S VC vs Con-S VC), PA and AAO. Importantly, the differential PAH-metabolite concentrations correlated with numerous outcome-relevant variables (e.g., tricuspid annular plane systolic excursion, pulmonary vascular resistance).Conclusions In PAH, trans-RV and transpulmonary metabolite gradients exist and correlate with haemodynamic determinants of clinical outcome. The most pronounced differential trans-R V gradients are known to be involved in lipid metabolism/lipotoxicity, that is, accumulation of long chain FAs. The identified accumulation of dicarboxylic acids and acylcarnitines likely indicates impaired beta-oxidation in the hypertensive RV and represents emerging biomarkers and therapeutic targets in PAH.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Biomarker ; Hemodynamics ; Human ; Lipidomics ; Metabolites ; Metabolomics ; Omics ; Pah ; Trans-rv Gradient ; Transpulmonary Gradient ; β-oxidation; Heart-failure; Lipotoxicity; Oxidation; Children; Alpha

ISSN (print) / ISBN 1355-6037

e-ISSN 1468-201X

Journal Heart

Quellenangaben Volume: 106, Issue: 17, Pages: 1332-1341

Publisher BMJ Publishing Group

Publishing Place British Med Assoc House, Tavistock Square, London Wc1h 9jr, England

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute of Bioinformatics and Systems Biology (IBIS)
CF Metabolomics & Proteomics (CF-MPC)
Molekulare Endokrinologie und Metabolismus (MEM)